The gospel of over 15 million atrial fibrillation patients
Time of Update: 2022-04-15
Recently, there is good news that Sanofi's new anti-arrhythmic drug, Midarone Dronedarone Hydrochloride Tablets, has been launched in China for sinus rhythm patients with a history of paroxysmal or persistent atrial fibrillation (AF).
The relatively strong pattern of the coke market is not over yet there are still stories about coking capacity reduction at the end of the year
Time of Update: 2022-02-11
B Future supply: The gap in capacity replacement will be filled next year As we all know, the stronger-than-expected implementation of coking capacity reduction in Shanxi Province is the direct reason for the strong increase in coke prices.
A study of nearly 100,000 people in the UK reveals that the infection rate of the Delta strain in the fully vaccinated population has dropped by 2/3
Time of Update: 2021-08-29
According to a report from the British Government Network on the 4th, REACT-1, one of the UK's national new coronavirus infection tracking studies, announced the latest results, saying that compared with unvaccinated people, the new crown virus infection rate of people who have completed vaccination is 1/3 of the former.
Reduce the risk of death by 31%, the innovative treatment of cervical cancer terminates phase 3 clinical trials early
Time of Update: 2021-04-28
Today, Sanofi and Regeneron jointly announced that the PD-1 inhibitor Libtayo (cemiplimab) jointly developed by the two parties will be used as a monotherapy for the treatment of stage 3 patients with relapsed/metastatic cervical cancer.
Selinexor Phase III Clinical Research SEAL data is published and orally reported on CTOS 2020
Time of Update: 2020-12-20
· Selinexor can significantly improve the progression-free survival of patients with advanced non-removable decissive fatty sarcoma who have previously received at least 2 treatment options (risk ratio of 0.70, p=0.023) According to SEAL Phase III clinical data, Selinexor has great potential in the field of solid tumors On December 1, Deki Pharmaceuticals announced that its strategic partner Karyopharm Therapeutics Inc.
Industry: In the medium and long term, the three types of companies in the pharmaceutical sector deserve attention
Time of Update: 2020-04-08
Pharmaceutical Network Market Analysis: At present, domestic pharmaceutical investment can be divided into short-term investment and medium- and long-term investment two stages In the short term, dem